Journal profile · Materials Science, Biomaterials
Biomaterials Advances
ISSN 2772-9508 · Elsevier BV · NETHERLANDS · Monthly · Founded 1993
Biomaterials Advances: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 6.62; hybrid open access; APC about USD 3,750; median 81 days to acceptance (148 articles, last 24 months); 435 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Biomaterials Advances is published by Elsevier BV and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Bone Tissue Engineering Materials, Electrospun Nanofibers in Biomedical Applications and Wound Healing and Treatments, together about 32.4% of its articles. Its main subfields are Biomedical Engineering and Biomaterials. (generated from OpenAlex topic counts and CAS ranking data)
Biomaterials Advances includes topics at the interface of the biomedical sciences and materials engineering. These topics include: Bioinspired and biomimetic materials for medical applicationsMaterials of biological origin for medical applicationsMaterials for "active" medical applicationsSelf-assembling and self-healing materials for medical applications"Smart" (i.e., stimulus-response) materials for medical applicationsCeramic, metallic, polymeric, and composite materials for medical applicationsMaterials for in vivo sensingMaterials for in vivo imagingMaterials for delivery of pharmacologic agents and vaccinesNovel approaches for characterizing and modeling materials for medical applicationsManuscripts on biological topics without a materials science component, or manuscripts on materials science without biological applications, will not be considered for publication in Biomaterials Advances. New submissions are first assessed for language, scope and originality (plagiarism check) and can be desk rejected before review if they need English language improvements, are out of scope or present excessive duplication with published sources.Biomaterials Advances sits within Elsevier's biomaterials science portfolio alongside Biomaterials, Materials Today Bio and Biomaterials and Biosystems. Biomaterials Advances offers authors rigorous peer review, rapid decisions, and high visibility. We look forward to receiving your submissions!
From the journal's Aims & Scope
Research area (LetPub): Materials Science, Biomaterials
Editor-in-chief Manuel Salmeron-SanchezPublisher website
Editorial board by country: 9 in mainland China (about 20%); most named United States 13, Mainland China 9, United Kingdom 7, Spain 3, Netherlands 2 (45 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Bone Tissue Engineering MaterialsEngineering14.2%
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science9.8%
- Wound Healing and TreatmentsMedicine8.5%
- Nanoplatforms for cancer theranosticsEngineering7.9%
- 3D Printing in Biomedical ResearchEngineering7.6%
- Graphene and Nanomaterials ApplicationsEngineering4.9%
- Tissue Engineering and Regenerative MedicineMedicine4.7%
- Nanoparticle-Based Drug DeliveryMaterials Science4.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Materials Science, Biomaterials | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Materials Science, Biomaterials | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Materials Science, Biomaterials | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.62LetPub ·
- Impact factor (publisher)
- 6.7Publisher website ·
- CiteScore 2026-06
- 13.6LetPub ·
- CiteScore (publisher)
- 13.6Publisher website ·
- SJR 2026-06
- 1.14LetPub ·
- SNIP 2026-06
- 1.03LetPub ·
- h-index
- 104LetPub ·
- h-index
- 57OpenAlex ·
- i10-index
- 1,002OpenAlex ·
- 2-year mean citedness
- 5.41OpenAlex ·
- Self-citation rate
- 3%LetPub ·
- Share of gold OA articles
- 26.49%LetPub ·
Volume
- Articles per year
- 385LetPub ·
Articles by year OpenAlex count · 2,213 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 452 | 135 | 351 |
| 2025 | 435 | 133 | 2,078 |
| 2024 | 333 | 131 | 4,174 |
| 2023 | 391 | 153 | 7,079 |
| 2022 | 518 | 142 | 12,842 |
| 2021 | 82 | 30 | 3,001 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
81 daysMedian, submission to acceptance · P25–P75 62 days – 113 days
- Acceptance to online
- median 2 days (148 articles)
- Submission to online
- median 84 days
- Sample
- 148 articles with submission and acceptance dates (1,015 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 7.2 weeksLetPub ·
- Average acceptance (community reports)
- 43%LetPub ·
- Submission to first decision
- 4 daysPublisher website ·
- First decision after review
- 35 daysPublisher website ·
- Submission to acceptance
- 81 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,750 / EUR 3,510 / GBP 3,000 / JPY 465,110 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Highlights
- Required
Article types accepted2
- letters intended for rapid publicationsLetters intended for rapid publicationsLength not stated
- original research work not already publishedOriginal research work not already publishedLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Publishing ethics policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Monthly
- Founded
- 1993
- ISSN
- 2772-9508
- Print ISSN
- 2772-9516
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Biomaterials Advances
What CAS zone is Biomaterials Advances in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biomaterials Advances is in Zone 2 of Medicine, and in Zone 2 of the minor category Materials Science, Biomaterials; it is a Top journal. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Biomaterials Advances?
The latest impact factor listed by LetPub is 6.62; CiteScore 13.6, h-index 57.
How long does peer review take at Biomaterials Advances?
Based on the dates recorded on 148 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 81 days (interquartile range 62–113 days); authors report an average review time of about 7.2 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Biomaterials Advances?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Biomaterials Advances based?
Of the 45 board members whose country the journal's board page names, 9 (about 20%) are in mainland China; the countries named most often are United States (13), Mainland China (9) and United Kingdom (7). Counted from the institutions listed on the board page; for reference only.
Which databases index Biomaterials Advances?
According to LetPub and DOAJ records, Biomaterials Advances is indexed in SCIE and Scopus.
Is Biomaterials Advances open access, and what is the APC?
Biomaterials Advances is a hybrid journal. For open-access publication: APC about USD 3,750.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .